News
The Duke Human Vaccine Institute plays an integral role in modernizing flu vaccines.
Duke is the only institution to receive a contract in each of the three CIVICs components, including work to design and evaluate influenza vaccine approaches, manufacture and evaluate the safety and toxicity of vaccine platforms, and conduct clinical trials for influenza vaccines.
Duke Health Leads Its First Clinical Trial Testing a New Universal Flu Vaccine
Duke Health is leading its first clinical trial under a large federal initiative to develop a new-generation flu vaccine.
Thomas Denny: Overseeing Duke's Vaccine Research Enterprise
As chief operating officer at the Duke Human Vaccine Institute (DHVI), Thomas Denny is in the unique position of helping people fight flu and HIV, developing the next generation of COVID-19 vaccines, and all the while leading an annual $120 million enterprise.
Duke Human Vaccine Institute to Serve as National Coordinating Center in Fight Against Influenza, COVID-19 and Respiratory Viruses
DHVI receives $4.9 million grant from CDC to serve seven U.S. sites